BRPI0513370A - uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv) - Google Patents

uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)

Info

Publication number
BRPI0513370A
BRPI0513370A BRPI0513370-0A BRPI0513370A BRPI0513370A BR PI0513370 A BRPI0513370 A BR PI0513370A BR PI0513370 A BRPI0513370 A BR PI0513370A BR PI0513370 A BRPI0513370 A BR PI0513370A
Authority
BR
Brazil
Prior art keywords
hcv
interferon
cyclosporine
pegylated
hepatitis
Prior art date
Application number
BRPI0513370-0A
Other languages
English (en)
Inventor
Catherine Cornu-Artis
Guylaine Vachon
Yoko Uryuhara
Kazuo Asakawa
Reinhild Elisabeth Mertes
Shinsyou Yoshiba
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0513370A publication Critical patent/BRPI0513370A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE UMA COMBINAçãO DE CICLOSPORINA E INTERFERONAS PEGUILADOS PARA TRATAMENTO DE HEPATITE C (HCV).Refere-se a um método de tratamento de um paciente tendo uma infecção por HCV, método que compreende administrar ao dito paciente uma ciclosporina A ou um derivado de ciclosparina A em associação com um conjugado de interferona a um polímero solúvel em água em uma quantidade eficaz para aliviar ou eliminar um ou mais sinais ou sintomas de HCV.
BRPI0513370-0A 2004-07-14 2005-07-13 uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv) BRPI0513370A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016583 2004-07-14
PCT/EP2005/007633 WO2006005610A1 (en) 2004-07-14 2005-07-13 Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)

Publications (1)

Publication Number Publication Date
BRPI0513370A true BRPI0513370A (pt) 2008-05-06

Family

ID=34972493

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513370-0A BRPI0513370A (pt) 2004-07-14 2005-07-13 uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)

Country Status (15)

Country Link
US (1) US7671017B2 (pt)
EP (1) EP1778272B1 (pt)
JP (1) JP2008506648A (pt)
KR (1) KR20070036175A (pt)
CN (1) CN1984671A (pt)
AT (1) ATE497775T1 (pt)
AU (1) AU2005261868B2 (pt)
BR (1) BRPI0513370A (pt)
CA (1) CA2573207C (pt)
DE (1) DE602005026294D1 (pt)
ES (1) ES2359925T3 (pt)
MX (1) MX2007000503A (pt)
PL (1) PL1778272T3 (pt)
RU (1) RU2394589C2 (pt)
WO (1) WO2006005610A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP2337583A1 (en) * 2008-09-17 2011-06-29 Boehringer Ingelheim International GmbH Combination of hcv ns3 protease inhibitor with interferon and ribavirin
WO2010069809A1 (en) * 2008-12-18 2010-06-24 F. Hoffmann-La Roche Ag Biomarkers for hcv treatment response
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
SG173180A1 (en) 2009-01-30 2011-09-29 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112012033022A2 (pt) 2010-06-24 2016-12-20 Genosciense Pharma Sas tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
SG11201601274QA (en) 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
ATE148469T1 (de) 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
AR031010A1 (es) 2000-10-19 2003-09-03 Fujisawa Pharmaceutical Co Una composicion farmaceutica, util para inhibir el dano celular
AU2003223913A1 (en) * 2002-04-05 2003-10-20 Viromics Gmbh Agents for treating less thanigreater thanflaviviridaeless than/igreater than infections
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
UA88484C2 (ru) 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
CA2587793A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
JP2008506648A (ja) 2008-03-06
EP1778272B1 (en) 2011-02-09
ES2359925T3 (es) 2011-05-30
ATE497775T1 (de) 2011-02-15
RU2007105354A (ru) 2008-09-10
AU2005261868B2 (en) 2009-01-15
MX2007000503A (es) 2007-03-08
WO2006005610A1 (en) 2006-01-19
EP1778272A1 (en) 2007-05-02
US20080138316A1 (en) 2008-06-12
KR20070036175A (ko) 2007-04-02
US7671017B2 (en) 2010-03-02
AU2005261868A1 (en) 2006-01-19
PL1778272T3 (pl) 2011-07-29
CA2573207C (en) 2013-04-16
RU2394589C2 (ru) 2010-07-20
DE602005026294D1 (de) 2011-03-24
CA2573207A1 (en) 2006-01-19
CN1984671A (zh) 2007-06-20

Similar Documents

Publication Publication Date Title
PL1778272T3 (pl) Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
EP2583677A3 (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
ATE490778T1 (de) Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
WO2006110655A3 (en) Compounds, compositions and methods for the treatment of poxvirus infections
EP2081435A4 (en) HAMMER OF BRUTON TYROSINE KINASE
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
BR0306993A (pt) Polìmero de polialquilenoglicol ativado; composição farmacêutica; método para tratar um paciente que tem uma infecção viral suscetìvel; e método para tratar um paciente suspeito de ter infecção por hepatite c
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
AR039915A1 (es) Tratamiento de la hepatitis c en la poblacion asiatica
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
MXPA05007901A (es) Terapia de combinacion para hcv.
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
UY28555A1 (es) Terapia de combinación para la infección de hcv
FR2875501B1 (fr) Nouveaux derives peptidiques, compositions et utilisations dans un traitement therapeutique de l'infection par un herpesvirus
AR067453A1 (es) Conjugados peptido - polimero
HK1125572A (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2314 DE 12-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.